Medical Writing Authors and Authorship Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature

Volume 25, Issue 1 - Authors and Authorship

Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature


This interview provides solutions to some of the common pitfalls that face medical writers when working with large teams. Practical tips are provided on key topics including manuscript planning, agreeing on key messages and the use of figures, tables and other contents, deciding on the criteria for authorship, and dealing with contributors who fall short of their commitments.

Download the full article


  1. Huth EJ, Case K. The URM: twentyfive years old. Science Editor 2004; 27: 17-21.
  2. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. JAMA 1997; 278: 579-585.
  3. Rennie D. Integrity in scientific publishing. Health Serv Res 2010; 45: 885-896.
  4. International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations). Available from:
  5. Matheson A. Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 2008; 3: 355– 382.
  6. Sismondo S. Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won’t cast light on. J Law Med Ethics. 2013;41:635-43.
  7. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336:1402-3.
  8. White Paper: Key Opinion Leader Identification and Selection. A Pharma Matters Report. Thomson Reuters, January 2009. Available from:
  9. Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature. Hastings Center Report 2016; 10.1002/hast.576.
  10. Wittek MR, Williams MJ, Carlson AM. Evidence development and publication planning: strategic process. Curr Med Res Opin. 2009;25:2723-7.
  11. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine 2007; 4: e286.
  12. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461-4.
  13. Hoekman J, Frenken K, de Zeeuw D, Heerspink HL. The geographical distribution of leadership in globalized clinical trials. PLoS One 2012; 7: e45984.
  14. Hirsch LJ. Conflicts of interest, authorship, and disclosures in industryrelated scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clin Proc. 2009;84: 811-21.
  15. Davidoff, F, C.D. DeAngelis, J.M. Drazen, M.G. Nicholls, J. Hoey et al. 2001. Sponsorship, authorship, and accountability. New England Journal of Medicine. 345:825-826.
  16. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004 Sep 15;292(11):1363-4
  17. Lessig L. “Institutional corruption” defined. J Law Med Ethics 2013; 41: 2-4.
  18. Foucault, M. (1980). The confession of the flesh. In M. Foucault (C. Gordon, Ed.), Power/knowledge: Selected interviews and other writings, 194–228. Brighton: Harvester Press.P 195.
  19. Horton R. The Dawn of McScience. New York Review of Books. March 11 2004.
  20. Drazen JM. Revisiting the commercialacademic interface. N Engl J Med 2014;372;19:1853-4.



Authors and Authorship
Letter from the Editor
President’s Message
Ghostwriting prevalence among AMWA and EMWA members (2005 to 2014)
The sun never sets on transparency
GPP3 – what is it, why is it necessary and what is new?
Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature
Perspective from a leading scientific author: An interview with Professor Ruth Roberts on authors and authoring
Authorship of clinical trial documents
Project management in medical publication writing: A less explored avenue in pharmaceutical companies and clinical research organisations
Never say never! Returning to full-time employment after freelancing
Fifth EMWA freelance business survey
Journal Watch
In the Bookstores
The Webscout
Regulatory Writing: Authorship issues in regulatory documents
English Grammar and Style
Medical Communication
Lingua Franca and Beyond
Gained in Translation
Medical Writing Teaching
Profile: An interview with Phil Leventhal
EMWA’s 2016 Webinar Programme
Out on our own


The Write Stuff Archive Contact Instructions for Authors Article Template (Word) Journal Policies

Editoral Board


Raquel Billiones


Evguenia Alechine

Jonathan Pitt

Managing Editor

Victoria White

Associate Editors

Anuradha Alahari

Jennifer Bell

Nicole Bezuidenhout

Claire Chang

Barbara Grossman

Sarah Milner

John Plant

Sampoorna Rappaz

Amy Whereat

Section Editors

Daniela Kamir


Jennifer Bell


Nicole Bezuidenhout 

Digital Communication

Somsuvro Basu

EMWA News 

Ana Sofia Correia 

Gained in Translation

Ivana Turek

Getting Your Foot in the Door

Wendy Kingdom / Amy Whereat

Good Writing Practice

Alison McIntosh 

In the Bookstores

Maria Kołtowska-Häggström

Lingua Franca and Beyond

Maddy Dyer


Lisa Chamberlain-James

Medical Communications/Writing for Patients

Payal Bhatia

Medical Devices

Evguenia Alechine

My First Medical Writing

Anuradha Alahari

News from the EMA

Adriana Rocha


Tiziana von Bruchhausen


Clare ChangZuo Yen Lee 

Regulatory Matters

Sam Hamilton

Regulatory Public Disclosure

Claire Gudex

Teaching Medical Writing

Louisa Ludwig-Begall / Sarah Kabani

The Crofter: Sustainable Communications

Louisa Marcombes

Veterinary Writing

Editors Emeritus

Elise Langdon-Neuner

Phil Leventhal

Layout Designer

Chris Monk